XKRX
102940
Market cap138mUSD
Oct 08, Last price
14,250.00KRW
1D
-3.32%
1Q
-66.15%
Jan 2017
-87.86%
IPO
-73.10%
Name
Kolon Life Science Inc
Chart & performance
P/E
7.51
P/S
0.89
EPS
1,897.72
Div yield, %
—
Shrs. gr., 5y
2.51%
Rev. gr., 5y
10.06%
Revenues
208.98b
+29.49%
Net income
24.84b
P
CFO
10.21b
P
Dividend
Dec 28, 2016300 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kolon Life Science Inc. is primarily engaged in the creation and distribution of pharmaceutical products and environmental materials. The company's operations are organized into two distinct units: Chemical and Bio. Its Chemical division manages both pharmaceutical activities and the development of specialty chemicals. In contrast, the Bio business unit is focused on providing contract development and manufacturing services for biopharmaceuticals. The enterprise was founded on April 21, 2000, and its corporate headquarters are situated in Seoul, South Korea.
Key people
Myeong Gwan Seo
Managing Director · since 2012
Tae Geun Choi
Assistant Managing Director
Beom Seop Lee
Assistant Managing Director
Assistant Managing Director
Sang Wu Lee
Assistant Managing Director
Sang Hu Park
Assistant Managing Director · since 2012
Dae Gyo Seo
Internal Auditor
Seon Jin Kim
Chief Executive Officer, Director · since 2023
Wung Yeol Lee
Director · since 2010
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||